Number of Clinical Trials 2022
Explore the number of clinical trials conducted in various countries; critical for medical research and innovation.
Newer data is available: Number of Clinical Trials by country 2024 →
Where does your country rank? Pick it to see its position.
Related Health statistics
More ↓Interactive Map
Complete Data Rankings
Analysis: These countries represent the highest values in this dataset, showcasing significant scale and impact on global statistics.
- #151
Papua New Guinea
- #150
Niger
- #149
New Caledonia
- #148
Myanmar
- #147
Republic of Moldova
- #146
Madagascar
- #145
China, Macao SAR
- #144
Liberia
- #143
Kyrgyzstan
- #142
Jamaica
Context: These countries or territories have the lowest values, often due to geographic size, administrative status, or specific characteristics.
Insights by country
Cambodia
Cambodia ranked #81 globally with a total of 7 clinical trials in 2022. This number is notably lower than the global average, reflecting the challenges faced by the country in advancing its clinical research capabilities. Factors such as limited funding for healthcare research, a developing regulatory environment, and a need for greater investment in medical infrastructure contribute to this situation. Additionally, Cambodia's focus on improving healthcare access and outcomes may gradually enhance its clinical trial landscape in the future.
Belarus
In 2022, Belarus ranked #94 globally with a total of 4 clinical trials. This figure is notably lower than many of its Eastern European neighbors, reflecting a regional average that is generally higher. The limited number of clinical trials can be attributed to factors such as a smaller population base and ongoing economic challenges, which may hinder investment in research and development within the healthcare sector.
Gabon
In 2022, Gabon ranked #95 globally with a total of 4 clinical trials. This figure is relatively low compared to other countries in the region, reflecting challenges in research infrastructure and funding. Gabon's limited number of clinical trials may be attributed to its smaller population and economic focus on natural resource extraction, which can divert attention from healthcare research initiatives.
Lebanon
In 2022, Lebanon ranked #69 globally with a total of 13 clinical trials. This figure is relatively low compared to regional peers, as countries like Israel and Turkey lead in clinical research activity. The limited number of clinical trials in Lebanon can be attributed to ongoing economic challenges and a complex regulatory environment that may hinder investment in healthcare research.
Ghana
In 2022, Ghana ranked #63 globally with a total of 17 clinical trials. This figure is relatively modest compared to leading countries in clinical research, such as the United States, which hosts thousands of trials annually. Ghana's clinical trial activity is influenced by its growing healthcare sector and increasing investments in medical research, driven by both local and international partnerships.
Denmark
In 2022, Denmark ranked #13 globally with a total of 363 clinical trials. This figure is significantly higher than the global average, reflecting Denmark's robust healthcare system and strong investment in medical research. The country's favorable regulatory environment and emphasis on innovation in pharmaceuticals contribute to its high number of clinical trials, making it an attractive location for international research collaborations.
China, Hong Kong SAR
In 2022, China, Hong Kong SAR ranked #25 globally with 128 clinical trials. This figure is notable as it reflects a robust healthcare research environment, particularly when compared to regional counterparts. The region benefits from a strong regulatory framework and significant investment in biotechnology, which fosters innovation and attracts international collaborations.
Jordan
In 2022, Jordan ranked #58 globally with a total of 24 clinical trials. This figure is relatively low compared to regional leaders, indicating a need for growth in clinical research activities. Factors contributing to this statistic include Jordan's strategic location as a healthcare hub in the Middle East and ongoing investments in medical infrastructure, which aim to enhance the country's research capabilities.
South Korea
In 2022, South Korea ranked #11 globally with a total of 464 clinical trials. This number is significantly higher than the global average, reflecting South Korea's robust healthcare system and advanced research capabilities. The country benefits from a strong emphasis on biotechnology and pharmaceuticals, supported by government policies that encourage innovation and investment in clinical research.
Hungary
In 2022, Hungary ranked #50 globally with a total of 31 clinical trials. This number is relatively low compared to leading nations in clinical research, reflecting a more modest research capacity in the region. Key drivers for this statistic include Hungary's well-established healthcare system and a growing interest in pharmaceutical research, bolstered by its strategic location in Central Europe, which facilitates collaboration with neighboring countries.
Analysis & Context
In 2022, the United States led the world in the Number of Clinical Trials with a staggering 6,826 trials, while globally, countries reported between 1 and 6,826 trials. The global median was 9, with an average of 140.50 trials per country. This data underscores the significant disparity in clinical research efforts across the globe.
Concentration of Clinical Research in Developed Nations
The distribution of clinical trials is heavily skewed towards developed countries, with the United States, Turkey (1,702), and China (1,357) leading the charge. This concentration can be attributed to several factors including robust healthcare infrastructure, greater funding opportunities, and regulatory environments conducive to research and development. For instance, the U.S. has a well-established network of research institutions and pharmaceutical companies that drive its high number of trials. Similarly, France (1,299) and the United Kingdom (725) benefit from strong public and private sector investments in healthcare innovation.
Minimal Clinical Trial Activity in Developing Regions
At the other end of the spectrum, several countries reported only 1 clinical trial in 2022, including Cuba, Kyrgyzstan, and Chad. The limited number of trials in these regions can often be linked to economic constraints, limited healthcare infrastructure, and less access to global pharmaceutical networks. These factors inhibit the ability of these nations to conduct and attract clinical research, thus impacting their contribution to global medical advancements.
Year-over-Year Growth and Decline
The data also highlights significant year-over-year changes in clinical trial numbers. The United States saw the largest increase, adding 690 trials, a growth of 11.2%. This increase may be driven by accelerated innovation and research investments, especially in the wake of the COVID-19 pandemic. Turkey experienced a notable increase of 441 trials, reflecting a 35.0% growth, possibly due to strategic government support for healthcare research.
Conversely, France experienced a decline of 88 trials, a reduction of 6.3%. This decrease could be linked to shifting research priorities or changes in regulatory policies. Similarly, Saudi Arabia and Brazil saw decreases of 28 and 23 trials respectively, which might reflect broader economic or policy challenges affecting their research sectors.
Implications for Global Health Innovation
The disparity in clinical trial numbers across countries has significant implications for global health innovation. Countries like the United States and China are positioned to lead in medical advancements due to their high levels of research activity. Meanwhile, countries with minimal trial numbers may face challenges in accessing cutting-edge treatments and participating in the global healthcare dialogue. To bridge this gap, international collaborations and investments in healthcare infrastructure are essential, particularly in developing regions.
The data from 2022 reflects not only the current state of clinical research but also highlights areas for potential growth and development in global health innovation. By understanding these patterns, policymakers and healthcare leaders can better strategize on fostering a more equitable distribution of medical research efforts worldwide.
Frequently Asked Questions About Number of Clinical Trials in 2022
Which country had the highest number of clinical trials in 2022?
The United States had the highest number of clinical trials in 2022, with a total of 6,826 trials.
Which country had the lowest number of clinical trials in 2022?
Cuba had the lowest number of clinical trials in 2022, conducting only 1 trial.
What was the average number of clinical trials conducted per country in 2022?
The average number of clinical trials conducted per country in 2022 was 140.
What was the median number of clinical trials conducted by countries in 2022?
The median number of clinical trials conducted by countries in 2022 was 9.
How many countries conducted only 1 clinical trial in 2022?
Ten countries conducted only 1 clinical trial in 2022.
Which countries were in the top 3 for the number of clinical trials conducted in 2022?
The top 3 countries for the number of clinical trials conducted in 2022 were the United States with 6,826 trials, Turkey with 1,702 trials, and China with 1,357 trials.
Data Source
Number of clinical trials | ClinicalTrials.gov via Our World in Data
Data produced by ClinicalTrials.gov, compiled and published by Our World in Data as "Number of clinical trials".
Visit Data SourceCite this page
Geo Factbook. (n.d.). Number of Clinical Trials by Country, 2022. Retrieved November 16, 2026, from https://geofactbook.com/fact/number-of-clinical-trials/2022
The figures on this page come from Number of clinical trials | ClinicalTrials.gov via Our World in Data. For academic work, cite the original source as well.
›Embed this ranking on your site
Free to embed with attribution. Shows the top 10 countries and links back to the full ranking.